

Total returns[†]

At 30 Apr 2024	1 Mth %	3 Mths %	1 Yr %	3 Yrs % p.a.	5 Yrs % p.a.	10 Yrs % p.a.	Incep % p.a. (Dec 2000)
OC Premium Small Companies Fund	(4.7)	5.0	14.4	4.1	7.2	9.2	10.5
S&P/ASX Small Ordinaries Accumulation	(3.1)	3.3	7.4	0.0	3.9	6.5	5.7
Outperformance	(1.6)	1.6	7.1	4.1	3.3	2.7	4.8
S&P/ASX Small Industrials Accumulation	(5.0)	2.1	10.4	(1.3)	2.6	6.3	5.8
Outperformance	0.4	2.8	4.0	5.4	4.6	2.9	4.7

Performance review

The Small-Cap recovery stalled in April with the OC Premium Small Companies Fund down -4.7% for the month. This was behind the S&P/ASX Small Ordinaries Accumulation Index but slightly ahead of the S&P/ASX Small Industrials Accumulation Index with were down -3.1% and -5.0%, respectively, in April.

Telix Pharmaceuticals (TLX, +16.8%) released an outstanding March 24 quarter update with sales of its Illuccix prostate cancer PET tracer 18% above the December 23 quarter, which likely implies both market share gains and growth in the total addressable market. **Lifestyle Communities (LIC, -23.2%)** downgraded settlement guidance citing a challenging macro-economic backdrop and a lag in the time it is taking their customers to sell their homes. The Fund has exited its position due to concerns about LIC's medium-term outlook. **HMC Capital (HMC, -10.8%)** was sold down as investors went 'risk-off' with the highly regarded alternative asset manager likely the victim of profit taking following a strong re-rating in the stock over the past six months. The Fund used the share price weakness to increase its holding.

Outlook

April was a challenging month in equity markets with tensions the Middle East escalating and unnerving investors with Iran and Israel trading missile strikes. Moreover, a raft of negative economic data out of the US and Australia again has commentators speculating that we could be facing a period of stagflation in the coming months. Equities, in particular longer duration growth stocks, sold off in April on the expectation that interest rates will need to stay higher for longer.


In the US, GDP growth slowed sharply to 1.6% on an annualised basis in the March quarter, while inflation has re-accelerated with the Personal Consumption Expenditure price index, the US Federal Reserves (the Fed) preferred gauge, ticking up to an annualised 3.4%. Interest rate cuts in the US are now likely to be on the backburner until the end of the year, with the Fed expected to shift to a hawkish bias at its FOMC committee meeting in early May. The US 10-year treasury yield moved sharply higher in April, towards 4.7%, as resurgent inflation has deferred expectations of rate cuts.

Domestic inflation data was likewise concerning in April with progress towards the RBAs 2-3% target having stalled. While

the Australian economy is cooling, services inflation is proving to be "sticky" and jobs data remains strong. Expectations of RBA rate cuts have been pushed out into early CY25, with some commentators now believing the next move from the RBA is for interest rates to rise (not fall).

The deterioration in the economic outlook in Australia and the US in April was the catalyst for several changes to the portfolio during the month, with our exposure to growth stocks pared back. Both the economic and geopolitical environment remain fluid, and we will continue to reposition the portfolio, if the need arises, as we aim to continue to generate strong long-term investment outcomes for our clients.

Performance Comparison of \$100,000 over 10 yrs*



Top 5 holdings[#]

Company	ASX Code
GQG Partners Inc.	GQG
Kelsian Group Limited	KLS
Mineral Resources Limited	MIIN
Seven Group Holdings Limited	SVW
Telix Pharmaceuticals Limited	TLX

[#] The top 5 portfolio holdings are in alphabetical order and may not be representative of current or future investments.

Key Facts

Fund Overview

The Fund is a long-only, benchmark-unaware unit trust. It primarily invests in 30 to 50 quality small to medium-sized Australian companies with sustainable business models, quality management and attractive investment fundamentals that are listed, or about to list, on the ASX.

Responsible entity

Copia Investment Partners

Inception date

December 2000

Benchmark

S&P/ASX Small Ordinaries Accumulation Index

Investment time frame

At least 5 years

Distribution

Half-yearly

Management fee

1.20% p.a. (including GST net of RITC)

Performance fee

20.5% (including GST net of RITC) of the amount the Fund outperforms its benchmark provided specific conditions are met including a minimum absolute 5% return.

Performance hurdle

S&P/ASX Small Ordinaries Accumulation Index

High-water mark

Yes

Typical Investment Exposure

Cash	0%-20%
Equities	80%-100%
Including:	
S&P/ASX 100 Constituents	0%-20%

Platforms

AMP MyNorth | Grow Wrap | Asgard | BT Panorama | CFS First Choice | CFS First Wrap | Hub 24 | Insignia (Expand) | Xplore (Linear) | Macquarie | MLC/Navigator | Netwealth | OneVue | Powerwrap | Praemium | DASH | Mason Stevens



CONTACT COPIA

1800 442 129 | clientservices@copiapartners.com.au | copiapartners.com.au

[†]The total return performance figures quoted are historical, calculated using end-of-month hard-close mid-prices and do not allow for the effects of income tax or inflation. Total returns assume the reinvestment of all distributions. The performance is quoted net of all fees and expenses. The index does not incur these costs. This information is provided for general comparative purposes. * The performance comparison of \$100,000 over 10 years is for illustrative purposes only. All returns shown are based on Australian dollar figures. Past performance is not a reliable indicator of future performance. The total returns shown are prepared on an ongoing basis (i.e. they include all ongoing fees and expenses and assume reinvestment of all distributions). They do not take personal taxation into account. The comparison with the S&P/ASX Small Ordinaries Accumulation Index is for comparative purposes only. Index returns do not allow for transactional, management, operational or tax costs. An index is not managed and investors cannot invest directly in an index.

Past performance is not a reliable indicator of future performance. Positive returns, which the OC Premium Small Companies Fund (the Fund) is designed to provide, are different regarding risk and investment profile to index returns. A performance fee of 20.5% is payable annually on any excess performance (after deducting the management fee) above the benchmark, S&P/ASX Small Ordinaries Accumulation Index, to 30 June. A performance fee is only payable where the Fund has returned 5% or more since the last performance fee was paid. This document is for general information purposes only and does not take into account the specific investment objectives, financial situation or particular needs of any specific reader. As such, before acting on any information contained in this article, readers should consider the appropriateness of the information to their needs. This may involve seeking advice from a qualified financial adviser. Copia Investment Partners Ltd (AFSL 229316, ABN 22 092 872 056) (Copia) is the issuer of the OC Premium Small Companies Fund (ARSN 098 644 976). A current PDS is available from Copia located at Level 47, 80 Collins Street (North Tower), Melbourne VIC 3000, by visiting ocfunds.copiapartners.com.au or by calling 1800 442 129 (free call). A person should consider the PDS before deciding whether to acquire or continue to hold an interest in the Fund. Any opinions or recommendation contained in this document are subject to change without notice and Copia is under no obligation to update or keep any information contained in this document current.

The rating issued October 2022 APIR OPS0002AU is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2022 Lonsec. All rights reserved.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned APIR OPS0002AU— February 2023) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>